OptimizeRx Corporation (OPRX) AI Stock Analysis

OptimizeRx Corporation provides digital health solutions to life sciences organizations, healthcare providers, and patients. Its core offerings include financial messaging tools and a virtual patient support center integrated directly into electronic medical records and e-prescribe systems, allowing healthcare professionals to access sample vouchers and co-pay coupons. The company delivers brand awareness, reminder ads, and therapeutic support messaging to assist clinical decision-making. Additionally, OptimizeRx offers tailored brand support services for pharmaceutical manufacturers, alongside a cloud-hosted Mobile Health Messenger platform and a HIPAA-compliant automated messaging platform for regimen compliance and patient engagement.

Annual revenue increased from $61.3M in FY2021 to $109.4M in FY2025, representing a 5-year revenue CAGR of 20.4%. Revenue expanded 18.8% in FY2025 following a 28.8% increase in FY2024. Profitability improved in FY2025, with gross margin reaching 63.3%, operating margin turning positive to 11.0%, and net income totaling $5.1M, compared to net losses of $20.1M in FY2024 and $17.6M in FY2023. However, results softened over the trailing twelve months, where revenue was $98.7M and operating margin was -0.4%. In the latest quarter ended June 30, 2026, quarterly revenue fell 29.8% year-over-year and quarterly earnings declined 66.8%.

As of June 30, 2026, OptimizeRx held $24.1M in cash and short-term investments and $19.5M in total debt, resulting in net cash of $4.6M. Total assets stood at $164.3M against shareholders' equity of $131.1M, with a debt-to-equity ratio of 0.15 and a current ratio of 5.58. In FY2025, operating cash flow and free cash flow both reached $18.7M. The business maintained low capital expenditures of $58,000 in FY2025, while its share count grew 3.2% over 5 years.

OPRX closed at $8.50 on October 16, 2026, giving it a market cap of $160.1M and an enterprise value of $138.5M. The stock trades at a trailing P/E of 35.4x, above the 24.6x median of its US-listed Healthcare peers. Its forward P/E of 5.6x, EV to EBITDA of 8.8x, and price-to-sales ratio of 1.6x trade below the peer group medians of 17.3x, 12.0x, and 4.1x, respectively. Over the past year, the shares dropped 57.0%, underperforming the 16.8% return for the S&P 500 (SPY).

Wall Street coverage consists of 5 Strong Buy and 1 Buy ratings, with zero Hold, Sell, or Strong Sell recommendations. The mean price target is $12.60, representing a 48.2% premium over the last close of $8.50. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $96.2M and EPS of $0.88, down 16.6%. Five analysts covering the next fiscal year forecast revenue of $106.6M and EPS of $1.04. OptimizeRx beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.

This page is an AI-written research summary of OptimizeRx Corporation (OPRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OPRX income statement, OPRX balance sheet, OPRX key metrics, OPRX analyst forecast, OPRX chart. See the OPRX stock overview for the latest quote and news.